Drugs & Targets FDA issues safety alert for squamous cell carcinoma and various lymphomas in scar tissue around breast implants September 16, 2022Vol.48 No.33
Drugs & Targets FDA issues revised draft guidance on charging for investigational drugs under an IND application September 09, 2022Vol.48 No.32
Drugs & Targets FDA accepts ImmunityBio’s BLA for bladder cancer therapy N-803 July 29, 2022Vol.48 No.30
Drugs & Targets FDA grants eltanexor with fast track designation; EU Commission designates eltanexor as an orphan medicinal product July 22, 2022Vol.48 No.29
Drugs & Targets FDA accepts BLA for mosunetuzumab in relapsed or refractory follicular lymphoma July 08, 2022Vol.48 No.27
Drugs & TargetsFree FDA approves Breyanzi in relapsed or refractory large B-cell lymphoma after one prior therapy July 01, 2022Vol.48 No.26
Drugs & TargetsFree FDA issues draft guidance on patient-focused drug development July 01, 2022Vol.48 No.26
Drugs & Targets FDA grants accelerated approval to Tafinlar + Mekinist in unresectable or metastatic solid tumors with BRAF V600E mutation June 24, 2022Vol.48 No.25
Drugs & Targets FDA grants Fast Track designation to IK-930 in unresectable NF2-deficient mesothelioma June 24, 2022Vol.48 No.25
